BRNS

Barinthus Biotherapeutics
BRNS

$1.32
0%
 

About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Employees: 130

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 15 [Q4 2023] → 15 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.28% less ownership

Funds ownership: 25.2% [Q4 2023] → 24.92% (-0.28%) [Q1 2024]

42% less capital invested

Capital invested by funds: $36.5M [Q4 2023] → $21.3M (-$15.2M) [Q1 2024]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3
127%
upside
Avg. target
$7.17
443%
upside
High target
$8
506%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Barclays
Carter Gould
127%upside
$3
Overweight
Maintained
13 Jun 2024
HC Wainwright & Co.
Yi Chen
506%upside
$8
Buy
Reiterated
7 Jun 2024
HC Wainwright & Co.
Yi Chen
506%upside
$8
Buy
Reiterated
16 May 2024
HC Wainwright & Co.
Yi Chen
506%upside
$8
Buy
Reiterated
22 Apr 2024
HC Wainwright & Co.
Yi Chen
506%upside
$8
Buy
Reiterated
19 Apr 2024

Financial journalist opinion